LISINOPRIL tablet

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Veiklioji medžiaga:

LISINOPRIL (UNII: E7199S1YWR) (LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)

Prieinama:

Direct_Rx

Vartojimo būdas:

ORAL

Recepto tipas:

PRESCRIPTION DRUG

Terapinės indikacijos:

1.1 Hypertension Lisinopril tablets, USP, are indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive

Produkto santrauka:

2.5 mg Tablets: white to off-white, capsule-shaped tablets, imprinted with ‘H 144’ on one side and plain on the other side. Bottles of 30 tablets Bottles of 100 tablets Bottles of 500 tablets 5 mg Tablets: yellow, capsule-shaped tablets, imprinted with ‘H 145’ on one side and plain on the other side. Bottles of 100 tablets Bottles of 1000 tablets 10 mg Tablets: light pink, capsule-shaped tablets, imprinted with ‘H 146’ on one side and plain on the other side. Bottles of 30 tablets Bottles of 100 tablets Bottles of 1000 tablets 20 mg Tablets: dark pink, capsule-shaped tablets, imprinted with ‘H 147’ on one side and plain on the other side. Bottles of 30 tablets Bottles of 100 tablets Bottles of 1000 tablets 30 mg Tablets: red, capsule-shaped tablets, imprinted with ‘H 148’ on one side and plain on the other side. Bottles of 30 tablets Bottles of 100 tablets Bottles of 500 tablets Bottles of 1000 tablets 40 mg Tablets: yellow, capsule-shaped tablets, imprinted with ‘H 149’ on one side and plain on the other side. Bottles of 100 tablets Bottles of 1000 tablets

Autorizacija statusas:

Abbreviated New Drug Application

Prekės savybės

LISINOPRIL- LISINOPRIL TABLET
DIRECT_RX
----------
LISINOPRIL
WARNING: FETAL TOXICITY
When pregnancy is detected, discontinue lisinopril as soon as possible
[see Warnings and
Precautions (5.1)].
Drugs that act directly on the renin-angiotensin system can cause
injury and death to the
developing fetus [see Warnings and Precautions (5.1)].
1.1 Hypertension
Lisinopril tablets, USP, are indicated for the treatment of
hypertension in adult patients and pediatric
patients 6 years of age and older to lower blood pressure. Lowering
blood pressure lowers the risk of
fatal and non-fatal cardiovascular events, primarily strokes and
myocardial infarctions. These benefits
have been seen in controlled trials of antihypertensive drugs from a
wide variety of pharmacologic
classes.
Control of high blood pressure should be part of comprehensive
cardiovascular risk management,
including, as appropriate, lipid control, diabetes management,
antithrombotic therapy, smoking cessation,
exercise, and limited sodium intake. Many patients will require more
than 1 drug to achieve blood
pressure goals. For specific advice on goals and management, see
published guidelines, such as those
of the National High Blood Pressure Education Program’s Joint
National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with different
mechanisms of action, have been shown in randomized controlled trials
to reduce cardiovascular
morbidity and mortality, and it can be concluded that it is blood
pressure reduction, and not some other
pharmacologic property of the drugs, that is largely responsible for
those benefits. The largest and
most consistent cardiovascular outcome benefit has been a reduction in
the risk of stroke, but reductions
in myocardial infarction and cardiovascular mortality also have been
seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the absolute risk
increase per mmHg is gr